GlobeNewswire by notified

Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate

Share
  • Integrated solution for process development and manufacturing of drug substance and drug product will facilitate the advancement of clinical development
  • The agreement meets Allarity’s needs for current and future commercial production of dovitinib and will support the Company’s planned NDA filing in 2021

Basel, Switzerland and Hoersholm, Denmark, 23September 2021 – Allarity Therapeutics A/S, a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers, and Lonza, a CDMO partner to the biopharma industry, today announced an agreement to develop and manufacture dovitinib. The agreement aims to commence manufacturing of dovitinib in 2022 to meet Allarity’s projected needs for bringing dovitinib to market following anticipated regulatory approvals.

Dovitinib represents Allarity’s most advanced clinical asset, targeting metastatic renal cell carcinoma (RCC) with possible use in other indications, such as liver cancer, breast cancer and various solid tumors. This pan-tyrosine kinase inhibitor targets fibroblast growth factor receptor, vascular endothelial growth factor receptor and other receptor tyrosine kinases.

Steve Carchedi, CEO, Allarity commented: “Entering this agreement with Lonza is an important step in our long-term preparations to take dovitinib towards commercialization. Allarity now has a robust agreement covering the production and ongoing supply of dovitinib that we will need in the years to come.”

Under the terms of the agreement, Lonza will leverage its capabilities for commercial manufacturing of small-molecules and oral solid dosage forms to provide Allarity with cGMP compliant drug product supply and regulatory support towards commercialization. Allarity will leverage Lonza’s global network, technical capabilities, and integrated solution covering both drug substance and drug product. The drug substance manufacturing and particle size reduction by micronization will be performed at Lonza’s facility in Visp (CH). The drug product manufacturing will take place at the Tampa, FL (US) facility.

Christian Dowdeswell, VP and Global Head, Commercial Development – Small Molecules, Lonza, added: “Our collaboration with Allarity Therapeutics demonstrates our commitment to supporting companies with their development pipeline. Our unique and comprehensive set of capabilities supporting drug substance through to drug product development and manufacturing enable Allarity to focus on dovitinib commercialization.”

About Allarity Therapeutics
Allarity Therapeutics (Nasdaq First North Growth Market Stockholm: ALLR.ST) develops drugs for personalized treatment of cancer guided by its proprietary drug response predictor technology, the DRP® platform. The Company has a mature portfolio of six drug candidates, including compounds in the pre-registration stage. The product portfolio includes: stenoparib (2X-121), a PARP inhibitor in Phase 2 for ovarian cancer; dovitinib, a pan-TKI in post-Phase 3 for renal cell carcinoma; IXEMPRA® (Ixabepilone), a microtubulin inhibitor approved in the U.S. for the treatment of breast cancer; LiPlaCis®, a liposomal formulation of cisplatin in Phase 2 trials for breast and prostate cancer, currently being developed by Smerud Medical Research International; 2X-111, a liposomal formulation of doxorubicin under manufacturing for Phase 2 in breast cancer, currently being developed by Smerud Medical Research International; and Irofulven, a DNA damaging agent in Phase 2 for prostate cancer, currently being developed by Lantern Pharma, Inc.

Follow Alarity on social media:
Facebook: https://www.facebook.com/AllarityTx/
LinkedIn: https://www.linkedin.com/company/allaritytx/
Twitter: https://twitter.com/allaritytx

About the Drug Response Predictor – DRP® Companion Diagnostic
Allarity uses its drug specific DRP® to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. By screening patients before treatment, the response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and prior clinical trial outcomes. DRP® is based on messenger RNA from the patient’s biopsies. DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in nearly 40 clinical studies that were examined, including an ongoing, prospective Phase 2 trial. The DRP® platform can be used in all cancer types and is patented for more than 70 anti-cancer drugs.

About Lonza
Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare sector.

Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 15,000 full-time employees, we comprise high-performing teams and individual talent that make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 2.5 billion with a CORE EBITDA of CHF 847 million in H1 2021. Find out more at www.lonza.com.

Follow @Lonza on LinkedIn
Follow @LonzaGroup on Twitter

Allarity Therapeutics Contact Details

InvestorRelations@allarity.com

Mike Beyer
US Media contact
Sam Brown, Inc.
Tel +1 312-961-2502
mikebeyer@sambrown.com

Thomas Pedersen
EU Media contact
Carrotize PR & Communications
Tel +45 6062 9390
tsp@carrotize.com

Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Tel: +46 11 32 30 732
ca@skmg.se

Lonza Contact Details

Victoria Morgan
Head of External Communications
Lonza Group Ltd
Tel +41 61 316 2283
victoria.morgan@lonza.com

Dr. Martina Ribar Hestericová
Trade Media Lead
Lonza Group Ltd
Tel +41 61 316 8982
martina.ribarhestericova@lonza.com

Dirk Oehlers
Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540
dirk.oehlers@lonza.com

Additional Information and Disclaimer (Lonza)
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking state-ments included in this news release due to various factors. Furthermore, except as otherwise re-quired by law, Lonza Group Ltd disclaims any intention or obligation to update the statements con-tained in this news release.

Forward-Looking and MAR Statements (Allarity Therapeutics)
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of Allarity’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning Allarity’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. Allarity makes nor undertakes any obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

This information is information that Allarity Therapeutics A/S is obliged to make public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication on September 23, 2021.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Greenland Resources Appoints Jens Moberg as Senior Advisor19.10.2021 15:57:02 CEST | Press release

TORONTO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Greenland Resources Inc. (NEO:MOLY, FSE:2LF) (“Greenland Resources” or the “Company”) is pleased to announce that it has created a European Advisory Board with the objective of providing strategic and technical input to corporate decision-making in respect of relevant stakeholders in the European industry ecosystem, with particular reference to the development of the Malmbjerg molybdenum deposit in east Greenland. To this extent, Mr. Jens Moberg will join as Senior Advisor. Jens has over twenty-five years of experience in international executive positions. Currently, he is the Chairman of the Board of Grundfos, a leading pump and water technology company with over 19,000 employees represented in more than 60 countries. He also acts as Member of the Board of Kirk Kapital A/S, a family owned financial investment firm with a heritage that stretches back to the world-famous LEGO name; and as a member of The Poul Due Jensen Foundation Board. To nam

VoltH2 Expands Management Team19.10.2021 15:50:29 CEST | Press release

JERSEY CITY, N.J., Oct. 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Vision Hydrogen Corporation (OTCQB:VIHD) (the “Company”) is pleased to announce that VoltH2, a Europe-based developer of green hydrogen production infrastructure projects that is 15.9% owned by the Company, has expanded its management team. VoltH2 continues to make significant progress in realizing its objectives and has made a number of strategic hires, increasing its core team of highly experienced commercial and engineering professionals to 10 individuals, with a plan to double the team headcount by Q2 2022 as the pace of business continues to increase. Since commencing operation in early 2020, VoltH2 has been successfully executing on its mission to design, develop and build scalable hydrogen production facilities at multiple strategic locations in Western Europe. Deploying only proven and commercial technologies in partnership with established energy-industry participants, VoltH2 has been awarded permits for

Benjamin Hill Updates on Planned Inaugural Drill Program With Outline of Prospective Targets19.10.2021 13:30:00 CEST | Press release

VANCOUVER, British Columbia, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Benjamin Hill Mining Corp. (CSE: BNN) (OTCBB: BNNHF) (“BHM” or the “Company”) Benjamin Hill Mining Corp. is pleased to announce that drill locations have been finalized for the upcoming inaugural drill program on our Sonora Gold property in Sonora, Mexico. The objective of the drill program is to test the continuity of high-grade mineralized shoots nested within vein and vein breccia sets. The program has been specifically designed to better understand the behavior of mineralization at depth and test structures that are thought to be open down dip and on strike. A total of 15 drill holes are initially planned, spread across the three most prospective exploration areas on the property. Targets and scale of the program are subject to change at the direction of management in collaboration with the experienced geological team. Greg Bronson, President of Benjamin Hill Mining Corp. states: "Everyone at Benjamin Hill is anticipati

Mandalay Resources Corporation Announces Production and Sales Results for the Third Quarter of 202119.10.2021 13:30:00 CEST | Press release

TORONTO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) announced today its production and sales results for the third quarter of 2021. Third Quarter 2021 Production Highlights: Consolidated saleable gold equivalent production of 33,121 ounces – highest quarterly result since Q4 2017;Consolidated 29,752 ounces of gold equivalent sold – highest quarterly amount in four years;Costerfield’s highest ever quarterly saleable gold equivalent production of 18,946 ounces; andCerro Bayo produced 2,925 ounces of gold equivalent. The Company expects Cerro Bayo’s overall contribution to be 9,000 – 10,000 ounces of gold equivalent by year end. Based on year-to-date production results, Mandalay anticipates that consolidated 2021 saleable production (not including production from Cerro Bayo) will be at the higher end of the previously provided production guidance range of the 105,000 – 117,000 ounces of gold equivalent. Dominic D

EthosEnergy CEO Ana Amicarella recognized as Top Executive for 202119.10.2021 13:00:00 CEST | Press release

San Antonio, Texas, Oct. 19, 2021 (GLOBE NEWSWIRE) -- San Antonio, Texas – EthosEnergy’s CEO, Ana Amicarella has been recognized as Top Executive of the Year during the Experience Power conference hosted by Power magazine. Power magazine honored innovative leaders from the power generation industry during an awards ceremony at the Experience Power conference last night. A worldwide call for nominations went out and submissions were narrowed down to a shortlist of award-worthy contenders into 15 categories. Ana Amicarella, CEO of EthosEnergy said: “I am honored to have won this award. But most of all, I am proud of everything our team has achieved over the last year despite challenging conditions.” Faced with outage cancellations and postponements due to COVID-19, and a depressed oil and gas sector, EthosEnergy’s reaction was to restructure the business to better align with customers and market dynamics. Ana Amicarella was appointed CEO in December 2019 with a mission to take EthosEnerg

Fobi Corporate Update Includes New Revenue Deals, Key Product Launches, New Verticals, Continued Partner Integrations And Further M&A Success And Activity19.10.2021 12:00:00 CEST | Press release

VANCOUVER, British Columbia, Oct. 19, 2021 (GLOBE NEWSWIRE) -- FOBI AI Inc. (TSXV: FOBI) (OTCQB: FOBIF:) (the "Company" or "FOBI"), a leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement is pleased to provide shareholders with the following corporate update regarding the following significant company initiatives. COMPANY OPERATING FROM A POSITION OF STRENGTH AS A RESULT OF STRONGEST BALANCE SHEET TO DATE With the increased number of revenue announcements this past quarter, increased volumes and execution on key strategic acquisitions the company has experienced an increase in inquiries from new retail investors and especially from larger institutions. The momentum in revenue deals has increased with entry into new verticals such as Azincourt, Kiaro and Empower this past quarter. In addition, the company has benefited this past quarter from further warrant and option conversion totaling an additional $2,167,188 CAD. The

RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS19.10.2021 11:07:00 CEST | Press release

RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS Auction date2021-10-19Loan2611 Coupon1.00 %ISIN-codeSE0012569572Maturity2026-11-12 Tendered volume, SEK mln1,000 +/- 500 Volume offered, SEK mln3,270 Volume bought, SEK mln1,000 Number of bids6 Number of accepted bids2 Average yield0.549 %Lowest accepted yield0.549 %Highest yield0.550 %% accepted at lowest yield 93.00 Auction date2021-10-19Loan2805 Coupon0.75 %ISIN-codeSE0015660139Maturity2028-05-12 Tendered volume, SEK mln500 +/- 250 Volume offered, SEK mln1,500 Volume bought, SEK mln500 Number of bids8 Number of accepted bids2 Average yield0.772 %Lowest accepted yield0.772 %Highest yield0.772 %% accepted at lowest yield 76.92